• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [16733 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2018     NIHR Health Services and Delivery Research programme Clinical leadership in service redesign using Clinical Commissioning Groups: a mixed-methods study
2018     Penn Medicine Center for Evidence-based Practice (CEP) Risk Factors for Surgical Site Infection and Infection Prevention in Elective Spine Surgery
2018     National Institute for Health and Care Excellence (NICE) Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 529
2018     NIHR Health Technology Assessment programme Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT
2018     NIHR Public Health Research (PHR) programme Cluster randomised controlled trial and economic and process evaluation to determine the effectiveness and cost effectiveness of a novel intervention [Healthy Lifestyles Programme (HeLP)] to prevent obesity in school children
2018     Penn Medicine Center for Evidence-based Practice (CEP) Venous Thromboembolism Prevention for Obese Patients
2018     National Institute for Health and Care Excellence (NICE) Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy. NICE technology appraisal guidance 530
2018     NIHR Public Health Research (PHR) programme Collaborative case management to aid return to work after long-term sickness absence: a pilot randomised controlled trial
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC)
2018     Penn Medicine Center for Evidence-based Practice (CEP) Scales for Assessing Patients Receiving Moderate Sedation
2018     National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. NICE technology appraisal guidance 531
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström’s macroglobulinaemia
2018     Penn Medicine Center for Evidence-based Practice (CEP) The Effect of Electronic Medical Record Alerts on Provider Wellness
2018     Agency for Healthcare Research and Quality (AHRQ) Attention deficit hyperactivity disorder: diagnosis and treatment in children and adolescents
2018     National Institute for Health and Care Excellence (NICE) Ocrelizumab for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 533
2018     NIHR Health Technology Assessment programme Lamotrigine for people with borderline personality disorder: a RCT
2018     National Institute for Health and Care Excellence (NICE) Dupilumab for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 534
2018     National Institute for Health and Care Excellence (NICE) Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine. NICE technology appraisal guidance 535
2018     NIHR Health Technology Assessment programme Improving the Quality of Dentistry (IQuaD): A cluster factorial randomised controlled trial comparing the effectiveness and cost-benefit of oral hygiene advice and/or periodontal instrumentation with routine care for the prevention and management of periodontal disease in dentate adults attending dental primary care
2018     Agency for Healthcare Research and Quality (AHRQ) Breastfeeding programs and policies, breastfeeding uptake, and maternal health outcomes in developed countries
2018     National Institute for Health and Care Excellence (NICE) Alectinib for untreated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 536
2018     National Institute for Health and Care Excellence (NICE) Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 537
2018     National Institute for Health and Care Excellence (NICE) Dinutuximab beta for treating neuroblastoma. NICE technology appraisal guidance 538
2018     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma. NICE technology appraisal guidance 540
2018     Health Information and Quality Authority (HIQA) Systematic review of cost-effectiveness – diagnosis and staging of patients with ovarian cancer
2018     The Regional Health Technology Assessment Centre (HTA-centrum) Effects of lung volume reduction with endobronchial valves in patients with severe chronic obstructive pulmonary disease. Updated report
2018     National Institute for Health and Care Excellence (NICE) Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. NICE technology appraisal guidance 541
2018     Health Information and Quality Authority (HIQA) Clinical effectiveness and cost-effectiveness of maternity early warning systems: systematic review update
2018     The Regional Health Technology Assessment Centre (HTA-centrum) Gender affirmation surgery for gender dysphoria - effects and risks
2018     National Institute for Health and Care Excellence (NICE) Cabozantinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 542
2018     Health Information and Quality Authority (HIQA) Irish Maternity Early Warning System: budget impact analysis
2018     The Regional Health Technology Assessment Centre (HTA-centrum) Effects of passive movement therapy in patients with stroke, spinal cord injury, or need of intensive care
2018     National Institute for Health and Care Excellence (NICE) Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 543
2018     The Regional Health Technology Assessment Centre (HTA-centrum) Efficacy of the Swedish model for physical activity on prescription
2018     National Institute for Health and Care Excellence (NICE) Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma. NICE technology appraisal guidance 544
2018     Agency for Care Effectiveness (ACE) https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidances/medical-technology-guidance/18f-fluorodeoxyglucose-positron-emission-tomography-with-computed-tomography-(fdg-pet-ct)-for-oncological-indications
2018     The Regional Health Technology Assessment Centre (HTA-centrum) Triage for prioritisation in the emergency department
2018     National Institute for Health and Care Excellence (NICE) Gemtuzumab ozogamicin for untreated acute myeloid leukaemia. NICE technology appraisal guidance 545
2018     National Institute for Health and Care Excellence (NICE) Padeliporfin for untreated localised prostate cancer. NICE technology appraisal guidance 546
2018     NIHR Health Technology Assessment programme Standing frames as part of postural management for children with spasticity. What is the acceptability of a trial to determine the efficacy of standing frames?
2018     NIHR Health Technology Assessment programme Combined feasibility and external pilot study to inform the design and conduct of the Fluids in Shock (FiSh) trial
2018     Agency for Healthcare Research and Quality (AHRQ) Drug therapy for early rheumatoid arthritis: a systematic review update
2018     National Institute for Health and Care Excellence (NICE) Tofacitinib for moderately to severely active ulcerative colitis. NICE technology appraisal guidance 547
2018     National Institute for Health and Care Excellence (NICE) Neuropad for detecting preclinical diabetic peripheral neuropathy. NICE medical technologies guidance 38
2018     NIHR Health Technology Assessment programme Gastrostomy versus nasogastric tube feeding for chemoradiation patients with head and neck cancer: the TUBE pilot RCT
2018     National Institute for Health and Care Excellence (NICE) Decitabine for untreated acute myeloid leukaemia (terminated appraisal). NICE technology appraisal guidance 548
2018     National Institute for Health and Care Excellence (NICE) Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency. NICE highly specialised technologies guidance 7
2018     Agency for Healthcare Research and Quality (AHRQ) Effectiveness of indoor allergen reduction in management of asthma
2018     National Institute for Health and Care Excellence (NICE) Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal). NICE technology appraisal guidance 549
2018     National Institute for Health and Care Excellence (NICE) iFuse for treating chronic sacroiliac joint pain. NICE medical technologies guidance 39
2018     National Institute for Health and Care Excellence (NICE) Vandetanib for treating medullary thyroid cancer. NICE technology appraisal guidance 550
2018     NIHR Health Technology Assessment programme Negative-pressure wound therapy versus standard dressings for adults with an open lower limb fracture: the WOLLF RCT
2018     National Institute for Health and Care Excellence (NICE) Lenvatinib for untreated advanced hepatocellular carcinoma. NICE technology appraisal guidance 551
2018     National Institute for Health and Care Excellence (NICE) Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia. NICE technology appraisal guidance 552
2018     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. NICE technology appraisal guidance 554
2018     National Institute for Health and Care Excellence (NICE) Peristeen Plus transanal irrigation system for managing bowel dysfunction. NICE medical technologies guidance 36
2018     NIHR Health Technology Assessment programme Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT
2018     National Institute for Health and Care Excellence (NICE) Thopaz+ portable digital system for managing chest drains. NICE medical technologies guidance 37
2018     Agency for Healthcare Research and Quality (AHRQ) Intermittent inhaled corticosteroids and long-acting muscarinic antagonists for asthma
2018     NIHR Health Technology Assessment programme A randomised controlled trial and economic evaluation of intraoperative cell salvage during caesarean section in women at risk of haemorrhage: the SALVO (cell SALVage in Obstetrics) trial
2018     NIHR Health Technology Assessment programme Nicotine preloading for smoking cessation: the Preloading RCT
2018     Health Quality Ontario (HQO) Bilateral Cochlear Implantation: A Health Technology Assessment
2018     NIHR Health Technology Assessment programme Closing five Emergency Departments in England between 2009 and 2011: the closED controlled interrupted time-series analysis
2018     Penn Medicine Center for Evidence-based Practice (CEP) Palliative care in the outpatient setting for patients with heart failure or advanced lung disease
2018     NIHR Health Technology Assessment programme AVURT: aspirin versus placebo for the treatment of venous leg ulcers a Phase II pilot randomised controlled trial
2018     Penn Medicine Center for Evidence-based Practice (CEP) Management structures for hospital nursing
2018     Agency for Healthcare Research and Quality (AHRQ) Lower limb prostheses: measurement instruments, comparison of component effects by subgroups, and long-term outcomes
2018     Penn Medicine Center for Evidence-based Practice (CEP) Treatment of severe acute medical-psychiatric comorbidity in hospitalized patients
2018     NIHR Health Technology Assessment programme Chondroitin sulphate for hand osteoarthritis: a randomised, placebo-controlled trial in primary care: the FACTUAL STUDY
2018     Penn Medicine Center for Evidence-based Practice (CEP) Diagnosis and treatment of gastrointestinal bleeding in patients with left ventricular assist devices
2018     NIHR Health Technology Assessment programme Long-term weight loss following a randomised controlled trial of a weight management programme for men delivered through professional football clubs: the Football Fans in Training follow-up study
2018     NIHR Health Technology Assessment programme Enteral lactoferrin to prevent infection for very preterm infants: the ELFIN RCT
2018     Penn Medicine Center for Evidence-based Practice (CEP) Cognitive therapy for schizophrenia
2018     NIHR Health Technology Assessment programme Understanding variation in ambulance service non-conveyance rates: a mixed methods study
2018     Penn Medicine Center for Evidence-based Practice (CEP) Nurse-directed discontinuation of continuous ECG monitoring among non-ICY inpatients
2018     NIHR Health Technology Assessment programme Intramedullary nail fixation versus locking plate fixation for adults with a fracture of the distal tibia: the UK FixDT RCT
2018     NIHR Health Technology Assessment programme The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation
2018     Agency for Care Effectiveness (ACE) Ivabradine for the treatment of chronic stable angina and chronic heart failure
2018     Agency for Care Effectiveness (ACE) Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease
2018     Agency for Care Effectiveness (ACE) LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD)
2018     Agency for Healthcare Research and Quality (AHRQ) Mobile applications for self-management of diabetes
2018     Agency for Care Effectiveness (ACE) Solifenacin for treating overactive bladder
2018     NIHR Health Technology Assessment programme Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT
2018     Agency for Care Effectiveness (ACE) Second-generation antipsychotic injections for treating schizophrenia
2018     Andalusian Health Technology Assessment Area (AETSA) Alectinib as monotherapy for the first-line treatment of adult patients with ALK positive advanced non-small cell lung cancer. EUnetHTA adopted HTA report
2018     Agency for Care Effectiveness (ACE) Lanthanum carbonate and sevelamer carbonate for treating hyperphosphataemia in patients with chronic kidney disease
2018     Agency for Healthcare Research and Quality (AHRQ) Noninvasive nonpharmacological treatment for chronic pain: a systematic review
2018     NIHR Health Technology Assessment programme Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT
2018     Andalusian Health Technology Assessment Area (AETSA) Midostaurin with standard chemotherapy in FLT3-positive acute myeloid leukaemia. EUnetHTA adopted HTA report.
2018     Andalusian Health Technology Assessment Area (AETSA) Quality criteria and good practices in organizations dedicated to the Health Technologies Assessment
2018     Agency for Healthcare Research and Quality (AHRQ) Nonsurgical treatments for urinary incontinence in women: a systematic review update
2018     Andalusian Health Technology Assessment Area (AETSA) Regorafenib indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib. EUnetHTA adopted HTA report.
2018     Health Information and Quality Authority (HIQA) Guidelines for the budget impact analysis of health technologies in Ireland
2018     NIHR Health Technology Assessment programme Self-Management education for adults with poorly controlled epILEpsy [SMILE (UK)]: a randomised controlled trial
2018     Health Information and Quality Authority (HIQA) Health technology assessment (HTA) of extending the national immunisation schedule to include HPV vaccination of boys
2018     Agency for Healthcare Research and Quality (AHRQ) Patient navigation models for lung cancer
2018     NIHR Health Technology Assessment programme Behavioural activation versus guided self-help for depression in adults with learning disabilities: the BeatIt RCT
2018     NIHR Health Technology Assessment programme Implementing the Creating Learning Environments for Compassionate Care (CLECC) programme in acute hospital settings: a pilot RCT and feasibility study
2018     Health Information and Quality Authority (HIQA) Risk factors for inclusion as criteria within the clinical guideline on risk classification during pregnancy: a modified Delphi study
2018     Agency for Healthcare Research and Quality (AHRQ) Physiologic predictors of severe injury: systematic review